Related Experiment Video
Updated: Jun 9, 2026
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Managing depressive disorders in patients with epilepsy
Psychiatry (Edgmont (Pa. : Township))
|September 1, 2010
Summary
Patients with epilepsy have higher rates of depression, impacting quality of life and increasing suicide risk. Current screening and treatment methods for depression in epilepsy are inadequate, requiring better management strategies.
Area of Science:
- Neurology
- Psychiatry
- Clinical Psychology
Background:
- Epilepsy is frequently comorbid with psychiatric disorders, particularly depression (9-22% prevalence).
- Depression in epilepsy is associated with reduced quality of life and elevated suicide risk (11.5% vs. 1.2% in general population).
- Despite its significance, depression in epilepsy often remains unrecognized and untreated.
Purpose of the Study:
- To highlight the challenges in recognizing and diagnosing depression in epilepsy patients.
- To discuss barriers to effective treatment of depression in this population.
- To emphasize the need for improved management strategies for depressive disorders in epilepsy.
Main Methods:
- Review of existing literature on depression in epilepsy.
- Analysis of diagnostic challenges and treatment limitations.
- Discussion of specific symptom constellations not captured by standard depression screening tools.
Main Results:
- Standard depression screening tools may miss specific symptoms in epilepsy patients, such as irritable mood or euphoria.
- Concerns about antidepressant effects on seizure thresholds and drug interactions contribute to undertreatment.
- Existing research on treating depression in epilepsy is limited, with no consistently effective treatments identified.
Conclusions:
- Depressive disorders in epilepsy present unique diagnostic and treatment challenges.
- There is a critical need for further research into effective and safe treatment options.
- Comprehensive management strategies are essential for improving patient outcomes.
Related Concept Videos
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...